Get the Stockscreener App
17.02
0.03%
0.092
Sionna Therapeutics Inc stock is traded at $17.02, with a volume of 11,878.
It is up +0.03% in the last 24 hours and down -15.61% over the past month.
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefit to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which Heads to insufficient CFTR function.
See More
Previous Close:
$17.11
Open:
$17.09
24h Volume:
11,878
Relative Volume:
0.16
Market Cap:
$703.86M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+9.36%
1M Performance:
-15.61%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$16.45
$17.30
1-Week Range:
$14.23
$17.30
52-Week Range:
$13.21
$24.90
Sionna Therapeutics Inc Stock (SION) Company Profile
Name
Sionna Therapeutics Inc
Sector
Industry
Phone
-
Address
-
Compare SION with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SION
Sionna Therapeutics Inc
|
17.10 | 703.86M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
498.33 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
678.01 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
577.05 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.72 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.13 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Sionna Therapeutics Inc Stock (SION) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-04-25 | Initiated | Guggenheim | Buy |
| Mar-04-25 | Initiated | Stifel | Buy |
| Mar-04-25 | Initiated | TD Cowen | Buy |
Sionna Therapeutics Inc Stock (SION) Latest News
Top 10 Insider Purchases Last Month - Insider Monkey
Sionna Therapeutics, Inc.’s Quiet Period To Expire on March 19th (NASDAQ:SION) - Defense World
Guggenheim Initiates Coverage on Sionna Therapeutics (NASDAQ:SION) - MarketBeat
Sionna Therapeutics (NASDAQ:SION) Earns Buy Rating from Analysts at TD Cowen - MarketBeat
February financings slowing, but year outpaces 2022-2023 - BioWorld Online
Investorideas.com adds New IPOs in Biotech, Technology, Homebuilder, Aerospace, Sports - Investorideas.com newswire
Is Sionna Therapeutics, Inc. (SION) Among Stocks With At Least $20 Million In Insider Spending Recently? - Insider Monkey
Stifel Nicolaus Initiates Coverage on Sionna Therapeutics (NASDAQ:SION) - Defense World
10 Stocks With At Least $20 Million In Insider Spending Recently - Insider Monkey
Sionna Therapeutics (NASDAQ:SION) Now Covered by Stifel Nicolaus - MarketBeat
TD Cowen Initiates Sionna Therapeutics at Buy -March 04, 2025 at 07:57 am EST - Marketscreener.com
Stifel Initiates Sionna Therapeutics at Buy With $32 Price Target -March 04, 2025 at 07:57 am EST - Marketscreener.com
TD Cowen initiates Sionna Therapeutics stock with Buy rating By Investing.com - Investing.com UK
Goldman Sachs starts Sionna Therapeutics with Early-Stage Biotech designation - TipRanks
Sionna Therapeutics: Promising NBD1 Stabilizers Poised to Challenge Vertex in the $11 Billion CF Market - TipRanks
Sionna Therapeutics: Innovative NBD1 Stabilizers and Strategic Synergies Drive Buy Rating - TipRanks
Guggenheim sets Sionna stock Buy rating, $45 target By Investing.com - Investing.com Canada
Innovative Approach to Cystic Fibrosis Treatment: Sionna Therapeutics’ Pioneering Pipeline Earns Buy Rating - TipRanks
Sionna Therapeutics, Inc. (SION): Among Stocks With At Least $10 Million In Insider Spending Recently - Insider Monkey
10 Stocks With At Least $10 Million In Insider Spending Recently - Insider Monkey
Sionna Therapeutics’ NBD1 stabilizers hold potential for cystic fibrosis - The Pharma Letter
Sionna Therapeutics’ IPO: A strategic shift in the cystic fibrosis market - Yahoo Finance
Sionna Therapeutics to Present at the 45th Annual TD Cowen Health Care Conference - The Manila Times
Sionna Therapeutics (SION) Surges in Nasdaq Debut Before Paring Gains - HPBL
Atlas Venture Fund Xi L.P Reports 6.5% Stake In Sionna Therapeutics As Of Feb 10 - Marketscreener.com
The Surprising Stock Insiders Can’t Stop Buying: What’s the Hype? - MotoPaddock
Sionna Therapeutics: The Biotech Stock Insiders Are Snapping Up! - Smartphone Magazine
Sionna Therapeutics: The Under-the-Radar Insider Favorite You’ve Been Missing - Anexartiti
Biopharma Gamble: Why Insiders Are Betting Big on Sionna Therapeutics - DSA
Why Insiders Are Betting Big on Sionna Therapeutics This Year - Bit Perfect Solutions
The Biopharma Gamble: Why Insiders Are Banking on Sionna Therapeutics - Elblog.pl
Is Sionna Therapeutics (SION) Among Stocks Insiders Are Buying This Year? - Insider Monkey
10 Stocks Insiders Are Buying This Year - Insider Monkey
A Buffett Buy, a Biotech IPO, and Other Big Insider Buying - 24/7 Wall St.
Sionna therapeutics sees $20.25 million stock purchase by TPG - MSN
Sionna Therapeutics’ $219.2 Million Upsized IPO - Global Legal Chronicle
Major Stock Acquisition Signals Confidence in Sionna Therapeutics - TipRanks
Insider Activity Recap: Monday’s Key Trades in US Stocks By Investing.com - Investing.com Australia
Sionna Therapeutics updates corporate bylaws post-IPO - Investing.com India
Sionna Therapeutics updates corporate bylaws post-IPO By Investing.com - Investing.com Australia
Ra capital management acquires $20.25m in Sionna Therapeutics stock By Investing.com - Investing.com South Africa
Major Stakeholders Make Bold Moves on Sionna Therapeutics Stock! - TipRanks
Ra capital management acquires $20.25m in Sionna Therapeutics stock - Investing.com
Orbimed advisors buys $9.9 million in Sionna Therapeutics stock By Investing.com - Investing.com Nigeria
Orbimed advisors buys $9.9 million in Sionna Therapeutics stock - Investing.com
Sionna Therapeutics director Peter Thompson acquires $9.9m in IPO shares - Investing.com Nigeria
Sionna Therapeutics Inc Stock (SION) Financials Data
There is no financial data for Sionna Therapeutics Inc (SION). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Sionna Therapeutics Inc Stock (SION) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Director |
Feb 10 '25 |
Buy |
18.00 |
1,125,000 |
20,250,000 |
6,923,365 |
| ORBIMED ADVISORS LLC | Director |
Feb 10 '25 |
Buy |
18.00 |
550,000 |
9,900,000 |
3,704,959 |
| Thompson Peter A. | Director |
Feb 10 '25 |
Buy |
18.00 |
550,000 |
9,900,000 |
3,704,959 |
| Booth Bruce | Director |
Feb 10 '25 |
Buy |
18.00 |
60,000 |
1,080,000 |
807,727 |
| Atlas Venture Fund XI, L.P. | 10% Owner |
Feb 10 '25 |
Buy |
18.00 |
60,000 |
1,080,000 |
807,727 |
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):